Live Breaking News & Updates on Sumi sukanya

Stay informed with the latest breaking news from Sumi sukanya on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Sumi sukanya and stay connected to the pulse of your community

Gennova likely to become second vaccine maker to receive advance from Centre

Express News Service
NEW DELHI: Pune-based vaccine maker Gennova could become the second company in India to receive advance payment from the Union government for manufacturing and stockpiling its Covid-19 vaccine, based on mRNA platform, that has shown encouraging results in Phase 1 trials.
Importantly, the manufacturer which is set to apply to the apex drug regulator to begin Phase 2 and 3 trials, is also tailoring the vaccine specifically against the delta variant of the Covid virus, which caused the devastating second wave in India.
The Centre last month had made an advance payment of Rs 1,500 crore to Hyderabad-based vaccine maker Biological E for procuring its Covid vaccine, still under Phase 3 clinical trials, marking the first such deal. By doing this, the government secured 30 crore doses, likely to be available by December end.

Hyderabad , Andhra-pradesh , India , Pune , Maharashtra , Bharat , Sumi-sukanya , Biotech-corporation , News-service , Bharat-biotech , ஹைதராபாத் , ஆந்திரா-பிரதேஷ்

Higher Covid vaccination may be why Delhi doing better than Mumbai

Higher Covid vaccination may be why Delhi doing better than Mumbai
As on July 23, Mumbai had 10,608 active Covid-19 cases while Delhi had only 573 coronavirus patients under treatment in hospitals or under home isolation, which is 178% less.
Share Via Email
| A+A A-
A health worker prepares to administer the Covishield vaccine to a woman at a government hospital in Noida. (Photo | AP)
NEW DELHI: The two most populous cities in India, Mumbai and Delhi, followed almost similar Covid-19 trajectories when the devastating second wave caught the country unawares, but the following weeks in these cities have thrown an epidemiological mystery with more questions than answers.

Delhi , India , Mumbai , Maharashtra , Sumi-sukanya , Oommen-john , Chandrakant-lahariya , George-institute-of-global-health , George-institute , Global-health , டெல்ஹி , இந்தியா

Centre begins inquiry into bird flu death of 11-year-old in Gurugram

Centre begins inquiry into bird flu death of 11-year-old in Gurugram
newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.

India , Haryana , Pune , Maharashtra , Sumi-sukanya , National-institute-of-virology , National-centre-for-disease-control , News-service , Disease-surveillance-programme , National-institute , National-centre , Disease-control

Despite claims of ramping up manufacturing, Covaxin laggard in vaccine pool, shows affidavit

Express News Service
NEW DELHI: In sharp contrast to the claims of Bharat Biotech on ramping up Covaxin’s production, only about 2.8 crore of its doses had been made available for the ongoing vaccination drive till June 12. This information was part of the 380-page affidavit the Union health and family welfare ministry filed in the Supreme Court on Saturday.
Of the over 32 crore vaccine doses administered so far, the share of Covishield, produced by Serum Institute of India, is more than 90%. The latest revelation on Covaxin’s low availability indicates the Hyderabad-based vaccine maker has been able to supply only about 50 lakh doses per month so far even though it has been claiming that it is constantly scaling up its manufacturing capacity and had reached 2 crore per month capacity in May.

India , Hyderabad , Andhra-pradesh , Bharat , Sumi-sukanya , News-service , Supreme-court-on , Serum-institute-of-india , Bharat-biotech , Supreme-court , Serum-institute , இந்தியா

Delta Plus is a potential concern: Virologist- The New Indian Express

Delta Plus is a potential concern: Virologist- The New Indian Express
newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.

India , Sumi-sukanya , Shahid-jameel , Trivedi-school-of-biosciences-at-ashoka-university , News-service , Trivedi-school , Ashoka-university , Delta-plus , இந்தியா , சுமி-சுகன்யா , ஷாஹித்-ஜமீல் , திரிவேதி-பள்ளி-ஆஃப்-உயிர்-அறிவியல்-இல்-அசோகா-பல்கலைக்கழகம்

Antibody cocktail for Covid emerges as ray of hope, but cost makes it prohibitive for most

Antibody cocktail for Covid emerges as ray of hope, but cost makes it prohibitive for most
Akanksha Chawala, a critical care pulmonologist at Apollo hospital in Delhi, said she had used the therapy in just two patients but the results had been extraordinary.
Share Via Email
| A+A A-
An artist paints 'No mask No Entry' graffiti at Chennai Central Railway station. (File Photo | Martin Louis, EPS)
Express News Service
NEW DELHI: A month after an antibody cocktail was approved for treating mild to moderate Covid-19 in high-risk patients in India, some leading private hospitals in the country have said that they have achieved remarkable results with its usage so far.

Wardha , Maharashtra , India , Delhi , Vellore , Tamil-nadu , Ghaziabad , Uttar-pradesh , Akanksha-chawala , Donald-trump , Sumi-sukanya-dutta , Anupam-singh

Final phase 3 trials data on Covaxin in July, says Bharat Biotech; experts question delay

Final phase 3 trials data on Covaxin in July, says Bharat Biotech; experts question delay
newindianexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newindianexpress.com Daily Mail and Mail on Sunday newspapers.

India , Russia , Russian , Bharat , Sumi-sukanya-dutta , Amar-jesani , Chandrakant-lahariya , Shahid-jameel , News-service , Central-drugs-standard-control-organisation , Sumi-sukanya , Bharat-biotech

Haffkine to start manufacturing 22.8 crore Covaxin doses from February 2022

The vaccine production process involves two stages – drug substance and final drug product, the official explained.

Mumbai , Maharashtra , India , Bharat , Indian-immunologicals , Sumi-sukanya , Haffkine-biopharma , Chiron-behring , Sandeep-rathod , News-service , Bharat-biotech , National-institute

Haffkine to start manufacturing 22.8 cr Covaxin doses from Feb 2021

The vaccine production process involves two stages – drug substance and final drug product, the official explained.

Mumbai , Maharashtra , India , Bharat , Indian-immunologicals , Haffkine-biopharma , Sumi-sukanya-dutta , Chiron-behring , Sandeep-rathod , News-service , Sumi-sukanya , Bharat-biotech

Preparing systematically for COVID-19 in kids, guidelines to be out soon: Centre

Preparing systematically for COVID-19 in kids, guidelines to be out soon: Centre
Dr VK Paul said that preparations will be made keeping 2.5 to 3 times that number in mind to tackle any future exigency.
Share Via Email
| A+A A-
A health worker collects swab sample of a child passenger at a COVID-19 testing counter at New Delhi railway station. (Photo | PTI)
Express News Service
NEW DELHI: The Centre is set to issue guidelines for Covid-19 management in kids and also to prepare hospital infrastructure to support a large number of kids in case the infectious disease hits them with more intensity in the coming months, authorities announced on Tuesday.

India , Delhi , Sumi-sukanya , Chandrakant-lahariya , News-service , Niti-aayog , Covid-in-kids , Ovid19 , Oronavirus , Ovid-treatment , K-paul , இந்தியா